HC Wainwright Reiterates "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $80.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price objective suggests a potential upside of 294.28% from the company's previous close.

Several other research analysts have also weighed in on the stock. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. UBS Group began coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Finally, Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Trading Down 1.8 %

Celldex Therapeutics stock opened at $20.29 on Tuesday. The company has a 50-day moving average price of $19.09 and a 200 day moving average price of $23.07. Celldex Therapeutics has a 12-month low of $14.40 and a 12-month high of $47.00. The stock has a market cap of $1.35 billion, a P/E ratio of -7.89 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, analysts forecast that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently made changes to their positions in CLDX. EverSource Wealth Advisors LLC boosted its position in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 2,933 shares during the period. Headlands Technologies LLC purchased a new position in Celldex Therapeutics during the 4th quarter worth approximately $81,000. KBC Group NV increased its position in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares during the period. Finally, AlphaQuest LLC increased its position in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.